title: Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse.
abstract: Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive markers to identify these patients who can stop imatinib without relapse.
authors: Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.
authors: Takayuki
authors: T
authors: Yoshimoto
authors: Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.
authors: Izuru
authors: I
authors: Mizoguchi
authors: Department of Hematology; Tokyo Medical University; Tokyo, Japan.
authors: Seiichiro
authors: S
authors: Katagiri
authors: Department of Hematology; Tokyo Medical University; Tokyo, Japan.
authors: Tetsuzo
authors: T
authors: Tauchi
authors: Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.
authors: Jun-Ichi
authors: JI
authors: Furusawa
authors: Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan ; Department of Immunology; Tokyo Medical University; Tokyo, Japan.
authors: Yukino
authors: Y
authors: Chiba
authors: Department of Immunology; Tokyo Medical University; Tokyo, Japan.
authors: Junichiro
authors: J
authors: Mizuguchi
authors: Department of Molecular Oncology; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.
authors: Junko H
authors: JH
authors: Ohyashiki
authors: Department of Hematology; Tokyo Medical University; Tokyo, Japan.
authors: Kazuma
authors: K
authors: Ohyashiki
keywords: NK cells; chronic myeloid leukemia; cytotoxic T lymphocytes; imatinib; immunosurvelliance; predictive marker